Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.38 |
| ▸ | EGLN2 | Q96KS0 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRM5 | P41594 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | STS | P08842 | 3/20 | 0.33 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30855045 | 1.00 | GPR119 (0.38) | GPR119EGLN2MEN1KMT2AGRM5 | |
| SCHEMBL14839868 | 0.84 | HRH2 (0.39) | GPR119EGLN2USP30NR1H2 | |
| SCHEMBL29334339 | 0.84 | GPR119 (0.38) | GPR119EGLN2CETP | |
| SCHEMBL14840026 | 0.83 | GPR119 (0.46) | GPR119EGLN2CETP | |
| SCHEMBL31224635 | 0.80 | HSP90AA1 (0.36) | MEN1KMT2ASTSUSP30ESR2 | |
| SCHEMBL29334072 | 0.78 | USP30 (0.38) | MEN1KMT2ASTSUSP30 | |
| SCHEMBL29334081 | 0.77 | STS (0.33) | MEN1KMT2ASTSUSP30ESR2 | |
| SCHEMBL29334170 | 0.76 | GPR119 (0.35) | GPR119MEN1KMT2AUSP30NR1H2 | |
| SCHEMBL30855145 | 0.76 | GPR119 (0.35) | GPR119MEN1KMT2AUSP30NR1H2 | |
| SCHEMBL14839844 | 0.74 | CKS1B (0.43) | GPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | GPR119 2964/4885EGLN2 140/4885MEN1 3695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.